RETSEVMO, also known by its generic name selpercatinib, is a targeted therapy medication used in the treatment of certain types of cancer. Specifically, it is designed to treat cancers that have alterations in the RET (rearranged during transfection) gene, including some thyroid cancers and non-small cell lung cancer (NSCLC). As a kinase inhibitor, RETSEVMO works by specifically blocking the activity of the RET protein, which can play a role in cancer cell growth and survival. By targeting this pathway, RETSEVMO can help to slow down or stop the growth of cancer cells that have RET gene alterations. It is typically prescribed for patients who have advanced cancer or for those whose cancer has spread to other parts of the body and have not responded to other treatments.